AddLife AB (publ) (LON:0REZ)
London · Delayed Price · Currency is GBP · Price in SEK | Market Cap | 1.40B -20.6% |
| Revenue (ttm) | 826.40M -0.3% |
| Net Income | 45.20M +83.8% |
| EPS | 0.37 +84.1% |
| Shares Out | n/a |
| PE Ratio | 30.92 |
| Forward PE | n/a |
| Dividend | 0.12 (0.08%) |
| Ex-Dividend Date | May 7, 2026 |
| Volume | 3,315 |
| Open | 143.20 |
| Previous Close | 143.70 |
| Day's Range | 141.30 - 143.80 |
| 52-Week Range | 133.00 - 207.60 |
| Beta | 1.57 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 16, 2026 |
About AddLife AB
AddLife AB (publ), together with its subsidiaries, provides instruments and equipment, consumables, and reagents primarily to medical care, research, colleges, and universities, as well as the food and pharmaceutical industries. The company operates in two segments, Labtech and Medtech. The Labtech segment offers products, solutions, and services in the areas of diagnostics, and biomedical research and laboratory analysis. It offers products and solutions, including analytical instruments, equipment, microscopes, consumables, and reagents, as w... [Read more]
Financial Performance
In 2025, AddLife AB's revenue was 10.44 billion, an increase of 1.52% compared to the previous year's 10.29 billion. Earnings were 560.00 million, an increase of 122.22%.
Financial numbers in SEK Financial StatementsNews
AddLife AB Earnings Call Transcript: Q1 2026
High margins sustained with EBITDA at 12.5% and strong growth in advanced products. Labtech and Medtech segments delivered robust performance, supported by recent margin-accretive acquisitions and improved European research funding.
AddLife AB Quarterly report: Q1 2026
AddLife AB has published its Q1 2026 quarterly earnings report on April 28, 2026.
AddLife AB Slides: Q1 2026
AddLife AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 28, 2026.
AddLife AB Earnings Call Transcript: Q4 2025
Q4 and full-year 2025 delivered strong profit and margin improvements, with robust cash flow and reduced net debt. Both Labtech and Medtech segments expanded margins, while acquisitions and portfolio optimization supported future growth.
AddLife AB Annual report: Q4 2025
AddLife AB has published its Q4 2025 annual report on February 4, 2026.
AddLife AB Quarterly report: Q4 2025
AddLife AB has published its Q4 2025 quarterly earnings report on February 4, 2026.
AddLife AB Slides: Q4 2025
AddLife AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 4, 2026.
AddLife AB Earnings Call Transcript: Q3 2025
Strong organic and acquired growth drove significant margin and profit improvements, with leverage reduced below target and robust cash flow. Platform acquisitions in Europe boosted segment performance, and a focus on advanced products strengthened margins.
AddLife AB Quarterly report: Q3 2025
AddLife AB has published its Q3 2025 quarterly earnings report on October 23, 2025.
AddLife AB Slides: Q3 2025
AddLife AB has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 23, 2025.
AddLife AB Earnings Call Transcript: Q2 2025
Margin and profit improvements drove EBITA above 12% in both segments, with 5% revenue growth and strong cash flow. Acquisition of Edge Medical and a robust M&A pipeline position the group for further growth.
AddLife AB Quarterly report: Q2 2025
AddLife AB has published its Q2 2025 quarterly earnings report on July 15, 2025.
AddLife AB Slides: Q2 2025
AddLife AB has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on July 15, 2025.